Australia markets close in 3 hours 42 minutes

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.13-0.60 (-8.92%)
At close: 4:00PM EST
Currency in USD

Valuation measures

Market cap (intra-day) 5324.36M
Enterprise value 3256.5M
Trailing P/E N/A
Forward P/E 1-3.19
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)3.30
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 6-2.75

Trading information

Stock price history

Beta (5Y monthly) 0.33
52-week change 317.43%
S&P500 52-week change 339.88%
52-week high 315.44
52-week low 32.72
50-day moving average 37.17
200-day moving average 35.15

Share statistics

Avg vol (3-month) 3933.01k
Avg vol (10-day) 3745.63k
Shares outstanding 552.91M
Float 38.1M
% held by insiders 111.80%
% held by institutions 156.50%
Shares short (11 Feb 2021) 42.42M
Short ratio (11 Feb 2021) 42.24
Short % of float (11 Feb 2021) 46.64%
Short % of shares outstanding (11 Feb 2021) 44.57%
Shares short (prior month 14 Jan 2021) 43.05M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)29 Sep 2020

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-37.95%
Return on equity (ttm)-86.73%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-70.96M
EBITDA -93.15M
Net income avi to common (ttm)-92.28M
Diluted EPS (ttm)-1.88
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)132.21M
Total cash per share (mrq)2.5
Total debt (mrq)64.36M
Total debt/equity (mrq)65.61
Current ratio (mrq)8.02
Book value per share (mrq)1.86

Cash flow statement

Operating cash flow (ttm)-77.31M
Levered free cash flow (ttm)-35.59M